Antibody against Na/K-ATPase inhibitor lowers blood pressure and increases vascular Fli1 in experimental preeclampsia.
Previous studies implicated cardiotonic steroids, including Na/K-ATPase inhibitor marinobufagenin (MBG), in the pathogenesis of preeclampsia (PE). We demonstrated that MBG induces fibrosis via mechanism involving inhibition of Fli1, a nuclear transcription factor and a negative regulator of collagen-1 synthesis. We hypothesized that PE blockade of increased MBG with antibody would lessen the fibrosis of umbilical arteries and lower the blood pressure in rats with PE. We tested 36 pregnant Sprague-Dawley rats in which 12 were made hypertensive by 1.8% Na supplementation (days 6-19 of gestation), 12 pregnant rats served controls. At day 19, PE rats received one intraperitoneal injection of polyclonal anti-MBG-4 antibody (0.5 ug/mL) for 4 hours. PE was associated with higher blood pressure (117±2 vs. 107±2 mmHg; P<.01), plasma MBG levels (1.54±0.34 vs. 0.49±0.11 nmol/L; P<.01), protein excretion (26 vs. 12 mg/24 hours), sFlt-1 (3-fold), decrease in Fli1 (7-fold) and increase in collagen-1 in aorta (4-fold) vs. control rats (all P<.01). In 12 rats treated with polyclonal anti-MBG-4 antibody blood pressure dropped (93±3 mmHg) and Fli1 was decreased much less (2-fold; P<.01 vs. nontreated rats). These results demonstrate that in experimental PE elevated MBG level is implicated in umbilical fibrosis via suppression of Fli1.